Andrew D. Krystal, M.D., M.S.
Dr. Krystal is the Director, Insomnia and Sleep Research Program, and Associate Professor with Tenure in Psychiatry and Behavioral Sciences, Duke University School of Medicine.
Within the past 12 months, Dr. Krystal reports research grant support, consulting relationship or advisory board member for Sanofi-Aventis, GlaxoSmithKline, King Pharmaceuticals, Inc., Merck & Co., Inc., Cephalon, Inc., Eli Lilly, Neurocrine Biosciences, Inc., Sepracor Inc., Pfizer Inc., Johnson & Johnson, Organon, Takeda Pharmaceuticals North America, Inc., Respironics, Neuronetics, Transoral, Neurogen, Somaxon, Research Triangle Institute and Novartis.
Estimated time to complete:
Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Albert Einstein College of Medicine is accredited
by the Accreditation Council for Continuing
Medical Education to provide continuing medical
education for physicians.
Upon completion of this Cyberounds®
, you should be able to:
- Describe new developments in research that have implications for changing the clinical management of insomnia
- Discuss strategies for optimal clinical management of insomnia
- Discuss the therapies that are available for the clinical management of insomnia and how to decide which to use in a given patient.